Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypersensitivity Reactions: Delayed Hypersensitivity Reactions01:29

Hypersensitivity Reactions: Delayed Hypersensitivity Reactions

Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
Transdermal Drug Delivery Systems01:18

Transdermal Drug Delivery Systems

Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
Diphtheria01:28

Diphtheria

Diphtheria is an acute, toxin-mediated infectious disease that primarily affects the upper respiratory tract. It is caused by Corynebacterium diphtheriae, a Gram-positive, pleomorphic rod that lacks spore-forming capability and exhibits a characteristic club-shaped morphology under microscopic examination. While C. diphtheriae can asymptomatically colonize mucosal surfaces, clinical disease manifests only when the bacterial strain is lysogenized by a specific β-corynephage. This phage...
Oral Drug Delivery Systems: Delayed-Release Systems01:11

Oral Drug Delivery Systems: Delayed-Release Systems

Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Documentation of biological treatment in asthma].

Pneumologie (Stuttgart, Germany)·2026
Same author

Sensitization profiles in patients with wheat-dependent exercise-induced anaphylaxis: practical aspects for allergy workup.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2026
Same author

Diagnosis and treatment of Hymenoptera venom allergy: S2k Guideline of the German Society of Allergology and Clinical Immunology (DGAKI) in collaboration with the Arbeitsgemeinschaft für Berufs- und Umweltdermatologie e.V. (ABD), the Medical Association of German Allergologists (AeDA), the German Society of Dermatology (DDG), the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery (DGHNOKC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Allergy and Environmental Medicine (GPA), German Respiratory Society (DGP), and the Austrian Society for Allergy and Immunology (ÖGAI).

Allergologie select·2023
Same author

Impact of climate change on allergic diseases in Germany.

Journal of health monitoring·2023
Same author

S2k-Leitlinie Diagnostik, Prävention und Therapie des Handekzems: S2k guideline diagnosis, prevention and therapy of hand eczema.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2023
Same author

Liebe Leserinnen und Leser.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2023

Related Experiment Video

Updated: May 30, 2026

Induction and Monitoring of Active Delayed Type Hypersensitivity (DTH) in Rats
13:26

Induction and Monitoring of Active Delayed Type Hypersensitivity (DTH) in Rats

Published on: July 19, 2007

Delayed pressure urticaria - dapsone heading for first-line therapy?

Sonja Alexandra Grundmann1, Sabine Kiefer, Thomas Anton Luger

  • 1Clinic and Polyclinic for Dermatological Diseases, Münster University Hospital, Germany. sonja.grundmann@ukmuenster.de

Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|July 21, 2011
PubMed
Summary
This summary is machine-generated.

Dapsone offers good to very good symptom relief for many patients with difficult-to-treat pressure urticaria. This treatment is well-tolerated and effective even after discontinuation, supporting early initiation.

More Related Videos

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Related Experiment Videos

Last Updated: May 30, 2026

Induction and Monitoring of Active Delayed Type Hypersensitivity (DTH) in Rats
13:26

Induction and Monitoring of Active Delayed Type Hypersensitivity (DTH) in Rats

Published on: July 19, 2007

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Area of Science:

  • Dermatology
  • Allergology
  • Pharmacology

Background:

  • Pressure urticaria, a rare physical urticaria subtype, presents significant treatment challenges.
  • Standard therapies like antihistamines (often high-dose) and montelukast provide incomplete symptom relief for many patients.
  • Exploring alternative treatments is crucial for managing refractory cases.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of dapsone as an early therapeutic alternative for pressure urticaria.
  • To establish a standardized dapsone treatment protocol for pressure urticaria.
  • To assess the risk-benefit ratio of early dapsone initiation.

Main Methods:

  • Retrospective survey of 31 patients treated with dapsone between 2003-2009.
  • Dapsone was used as an early alternative for persistent symptoms despite established therapies.
  • Standardized therapeutic regime implemented at the clinic.

Main Results:

  • Dapsone yielded good or very good results in 74% of patients with persistent symptoms.
  • Longer disease duration and co-existing chronic spontaneous urticaria were associated with reduced benefit (p<0.05).
  • No significant impact of age, gender, therapy duration, side-effects, or Met-Hb elevation on overall efficacy was observed.

Conclusions:

  • Dapsone therapy is well-tolerated and provides significant therapeutic benefit, which persists post-treatment.
  • The favorable risk-benefit profile supports early dapsone initiation in pressure urticaria management with adequate monitoring.
  • Dapsone represents a valuable treatment option for refractory pressure urticaria.